Chen ZX, Hohmann L, Banjara B, Zhao Y, Diggs K, Westrick SC. Recommendations to protect patients and health care practices from Medicare and Medicaid fraud. J Am Pharm Assoc. 2020 Nov;60(6):e60-5. doi: 10.1016/j.japh.2020.05.011
Pujol J, Fenoll R, Macia D, Martinez-Vilavella G, Alvarez-Pedrerol M, Rivas I, Forns J, Deus J, Blanco-Hinojo L, Querol X, Sunyer J. Airborne copper exposure in school environments associated with poorer motor performance and altered basal ganglia. Brain Behav. 2016 Apr 22;e00467. doi: 10.1002/brb3.467
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.
Schwab PE. Tobacco survey results/ cigarette sales in pharmacy: consumer research and analysis to support merchandising decisions. Poster presented at the 2010 American College of Apothecaries Mid-Year Meeting; March 2010. Memphis, TN. [abstract] J Am Pharm Assoc. 2010 Mar; 50(2).
Mehta S, Nagar SP, Aparasu R. Unmet prescription medication need in U.S. children. J Am Pharm Assoc. 2009 Nov;49(6):769-76.
Andrews EB, Gilsenan A, Cook SF. Therapeutic Risk Management Interventions: feasibility and Effectiveness. J Am Pharm Assoc. 2004 Jan 1;44(4):491-500.
Carlson AM, Stockwell-Morris L, Perfetto EM, Appel AM, Gilsenan AW. Quality of sleep in patients with osteoarthritis treated with extended-release and conventional etodolac. J Am Pharm Assoc. 1998 Jan;38(1):31-6. doi: 10.1016/S1086-5802(16)30297-2